Sanofi, Regeneron Dupixent approved in Canada for expanded use in kids with asthma
ALIOUI Mohammed Elamine/iStock via Getty Images         

Sanofi (NASDAQ:SNY) andÂ Regeneron Pharmaceuticals' (NASDAQ:REGN)Â DupixentÂ (dupilumab injection) was approved in Canada for expanded use as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.
The company said it is the sixth indication for Dupixent, its second in asthma, and its second indication in children aged six to 11 years.
The approval was based on data from a phase 3 trial, dubbedÂ VOYAGE,Â which enrolled 408 children aged six to 11 years with uncontrolled moderate- to severe asthma.